Skip to main
WGS

WGS Stock Forecast & Price Target

WGS Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

GeneDx Holdings is positioned for long-term success with its focus on providing genomic information at scale for pediatric and rare genetic disorders. With the potential for genomic testing to become the standard of care and advance precision medicine, GeneDx's offerings are well-positioned to drive improved outcomes and propel the company's growth. Despite short-term headwinds, the recently updated coverage policy and acquisition of Fabric Genomics provide a promising outlook for GeneDx's future profitability and potential market expansion.

Bears say

GeneDx Holdings is a market-leading company in the rare-disease testing industry, specializing in whole-exome and whole-genome sequencing for difficult-to-diagnose patients. However, the company has missed revenue expectations and lowered their guidance for fiscal year 2026, indicating potential challenges in scaling their business and expanding into other markets. Additionally, while the company's GUARDIAN study has shown promising results, it may take several more years before the data can be fully monetized and implemented into standard healthcare practices.

WGS has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GeneDx Holdings Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GeneDx Holdings Corp (WGS) Forecast

Analysts have given WGS a Strong Buy based on their latest research and market trends.

According to 5 analysts, WGS has a Strong Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $75.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $75.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GeneDx Holdings Corp (WGS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.